Search Results
Your search for ,ARE matches 21435 pages
Showing 7501 - 7550International Consortium Aims to Enhance Decision-Making in Hodgkin Lymphoma
Harmonization of big data in examining acute and long-term outcomes with contemporary treatment for pediatric and adult patients with Hodgkin lymphoma is yielding a new approach to inform future clinical trial design and enhance clinical decision-making, according to a statement by Rutgers Cancer...
Highlights From Complementary and Integrative Medicine Research and Implications for Clinical Practice
Due to COVID-19, this year’s ASCO Annual Meeting was convened using a virtual format. It was multidisciplinary, featuring more than 250 oral and 2,500 poster presentations from around the world in 24 disease-based and specialty tracks. Among the exciting talks in the session on symptoms and...
Underrepresentation of Black Patients in Cancer Clinical Trials: Public vs Pharmaceutical Sponsorship
Black patients are better represented in taxpayer-funded cancer clinical trials compared to trials run by pharmaceutical companies, although they remain underrepresented in clinical trials, regardless of sponsor. These results were published by Joseph M. Unger, PhD, and colleagues in JNCI Cancer...
FDA Announces Project Patient Voice to Communicate Patient-Reported Outcomes From Cancer Clinical Trials
The U.S. Food and Drug Administration (FDA) has launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer ...
Results of a COVID-19 and Cancer Consortium (CCC19) Cohort Study
As reported in The Lancet by Kuderer et al, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of severe COVID-19 in patients with cancer is associated with such factors as age, comorbidities, performance status, hematologic malignancy, and...
Expert Point of View: Michael S. Lee, MD, and Autumn McRee, MD
DESTINY-CRC01 study discussant, Michael S. Lee, MD, Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, called the findings “most promising” for the subsequent anti-HER2 treatment of HER2-positive metastatic colorectal cancer. The...
Trastuzumab Deruxtecan Shows Benefit in Refractory Colorectal Cancer
Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.1 T-DXd is an antibody-drug conjugate...
Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors
A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...
Prognosis of Patients With Stage III Melanoma According to AJCCv8 vs Independent Cohorts
In a study reported in the Journal of Clinical Oncology, Garbe et al found that melanoma-specific survival rates for patients with stage III disease differed markedly in three independent cohorts compared with those reported in American Joint Committee on Cancer version 8 (AJCCv8) stage III...
Lipophilic Statins May Reduce Mortality in Patients With Ovarian Cancer
Lipophilic statins—a type of medication commonly prescribed to lower blood cholesterol—were associated with reduced mortality in patients with ovarian cancer, according to a study presented by Kala Visvanathan, MD, MHS, and colleagues at the American Association for Cancer Research (AACR) Virtual...
ASTRO Issues Clinical Guideline on Radiation Therapy for Cervical Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline—ASTRO's first for cervical cancer—outlines indications and best practices for external-beam radiation...
Expert Point of View: Scott N. Gettinger, MD
Discussant for the CheckMate 227 and CheckMate 9LA trials, Scott N. Gettinger, MD, of Yale Cancer Center in New Haven, Connecticut, said: “There is tremendous interest in lung cancer to combine nivolumab plus ipilimumab, driven by the melanoma experience. However, combinations of immunotherapy come ...
Survival Disparities Seen in Hispanic Patients With Blood Cancers Living Near the United States/Mexico Border
A study by Bencomo-Alvarez et al investigating the incidence and survival for Hispanic patients with hematologic malignancies living along the United States/Mexico border in El Paso, Texas, has found that those patients with acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myeloid...
Positive Findings in NSCLC for First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy
It is becoming more challenging to select first-line therapy for advanced non–small cell lung cancer (NSCLC) for patients whose tumors have no EGFR or ALK alterations. The results of two different studies presented at the ASCO20 Virtual Scientific Program—CheckMate 227 and CheckMate 9LA—support the ...
Young Adults With Cancer May Benefit From Germline Genetic Testing
According to the National Cancer Institute, each year, about 70,000 adolescents and young adults (AYA)—those between the ages of 15 and 39—are diagnosed with cancer. Evidence suggests that some cancers found in AYA patients may have unique genetic and biologic features. A study that investigated...
FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia
Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...
SIR 2020 Virtual: Transarterial Chemoperfusion for Patients With Mesothelioma
A novel treatment for patients with advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology (SIR) 2020 Annual...
SIR 2020 Virtual: Holographic Visualization for Ablation of Liver Tumors
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of...
First-Line Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for SCLC Brain Metastases
In a cohort analysis reported in JAMA Oncology, Rusthoven et al found that first-line stereotactic radiosurgery was associated with similar outcomes as whole-brain radiotherapy in patients with small cell lung cancer (SCLC) brain metastases. As stated by the investigators, “Although stereotactic...
FDA Grants Accelerated Approval to Tazemetostat for Some Patients With Follicular Lymphoma
On June 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have...
Percutaneous Cryoablation vs Partial or Radical Nephrectomy for Early-Stage Kidney Cancer
A minimally invasive procedure that destroys cancer cells by freezing them may be an option other than surgery for treating early-stage kidney cancer. The two methods showed similar 10-year survival rates, with cryoablation showing a lower rate of complications, according to a study published by...
UKCCMP Prospective Cohort Study of COVID-19 Mortality in Patients With Cancer
As reported by Lee et al in The Lancet, a prospective cohort study from the United Kingdom performed by the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that increased risk of COVID-19 mortality in patients with cancer is associated with such factors as age, sex, and comorbidities,...
Tafasitamab Plus Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase II L-MIND trial reported in The Lancet Oncology, Gilles Salles, MD, and colleagues found that the combination of the Fc-enhanced anti-CD19 monoclonal antibody tafasitamab plus lenalidomide produced responses in patients with relapsed or refractory diffuse large B-cell lymphoma...
Immunogenomic Characteristics of Advanced Clear Cell Kidney Cancer Treated With Checkpoint Inhibitors
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitors. The research was presented during the ASCO20 Virtual Scientific...
Ripretinib in Previously Treated Patients With Advanced GIST: INVICTUS Trial
As reported in The Lancet Oncology by Jean-Yves Blay, MD, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib prolonged progression-free survival vs placebo in patients with advanced gastrointestinal stromal tumors (GIST) whose...
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or...
FDA Approves Pembrolizumab for Adults and Children With Tumor Mutational Burden–High Solid Tumors
On June 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H; ≥ 10 mutations/megabase [mut/Mb]) solid tumors, as determined by an ...
Effect of Functional Impairment on Hospitalized Patients With Cancer
New research published by Lage et al in JNCCN–Journal of the National Comprehensive Cancer Network found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission—meaning they needed assistance with activities of daily living like walking,...
Early Data Suggest Activity for Oral Selective Estrogen Receptor Degrader in Combination Regimen
The availability of an oral selective estrogen receptor degrader (SERD) would be good news for patients and clinicians as an alternative to intramuscular fulvestrant. The novel agent LSZ102 might fit the bill, based on early activity shown in combination with the targeted agents ribociclib and...
EHA25 Virtual: Roundup of Findings in Leukemia, Lymphoma, and More
Advances in the treatment of hematologic malignancies and some of their associated symptoms were presented during EHA25 Virtual, an ongoing online conference from the European Hematology Association (EHA). Advances in the Treatment of High-Risk CLL: CLL2-GIVe Results In the CLL2-GIVe trial, the...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented at the ASCO20 Virtual Scientific Program (Abstract 5077) and published as a brief report in JAMA Oncology, Ravi et al found that rechallenge with immune checkpoint inhibitor therapy was capable of producing responses in patients with metastatic renal cell carcinoma, including...
Expert Point of View: Julia R. White, MD
Julia R. White, MD, Professor of Radiation Oncology at The Ohio State University, Columbus, and the invited discussant of E2108, put these findings into context with three important studies evaluating the benefit of locoregional therapy for de novo stage IV breast cancer: the study from Tata...
Study Finds No Survival Benefit From Local Therapy for de Novo Metastatic Breast Cancer
Women presenting with newly diagnosed de novo metastatic breast cancer derived no additional survival benefit from surgery and radiotherapy given after systemic treatment, although the practice may reduce locoregional progression of disease, according to the results of the phase III E2108 study...
First-Line Platinum-Based Chemotherapy for Patients With Metastatic Pancreatic Cancer and Defects in Homologous Recombination Genes
Patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations, according to results from a study published by Park et al in Clinical Cancer Research....
Role of Race, Ethnicity, and Region in Mortality Among Pediatric Patients With Cancer Admitted to the ICU
Black and Hispanic children admitted to pediatric intensive care units for cancer treatment have significantly higher death rates than non-Hispanic white patients, according to findings from a study published by Laurens et al in Pediatric Critical Care Medicine. Nationwide, 8.5% of black and 8.1%...
Expert Point of View: Jesús G. Berdeja, MD
The importance of first-line therapy in multiple myeloma is that the first therapy typically achieves the most impact, and subsequent lines of therapy tend to be less effective, explained ENDURANCE study discussant Jesús G. Berdeja, MD, Director of Myeloma Research at the Sarah Cannon Research...
Carfilzomib Triplet Fails to Improve Outcomes vs Standard Bortezomib-Based Regimen in Newly Diagnosed Myeloma
For newly treated patients with standard- and intermediate-risk multiple myeloma who are not slated for immediate autologous stem cell transplantation (ASCT), the triplet regimen of carfilzomib/lenalidomide/dexamethasone (KRd) failed to improve progression-free survival vs the current...
National Cost of Cancer Care in the United States Expected to Rise to $246 Billion by 2030
According to research from the National Cancer Institute published by Mariotto et al in Cancer Epidemiology, Biomarkers, and Prevention, the national cancer-attributable cost for medical services and prescription drugs is expected to increase from $183 billion in 2015 to $246 billion by 2030—an...
Future COVID-19 Legislation Must Protect Patient Access to Cancer Care
ASCO joined hundreds of health organizations in signing four separate letters to Congress regarding future COVID-19 legislation as part of an effort to ensure patient access to high-quality, high-value cancer care during the pandemic. The four comment letters address different areas of the cancer...
New Recommendations Outline Approaches to Reduce Burnout in Oncology
An article recently published in JCO Oncology Practice (JCO OP) written by the ASCO Ethics Committee focused on the causes of burnout in oncology, as well as intervention methods. The article provides recommendations for individuals, organizations, and the Society to address burnout and ensure...
The Power of mCODE
ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity. Listen to the full podcast on...
Breastfeeding: A Public Health Strategy for Reducing Risk of Ovarian Cancer
Although early-stage disease is highly curable, most ovarian cancers are diagnosed at later stages due to a lack of effective screening. As a result, less than 50% of women survive beyond 5 years. Improving prevention by identifying modifiable risk factors could dramatically change the outcome of...
Expert Point of View: Kathleen N. Moore, MD
Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importance of studying patients with stable disease and less robust partial response, not just those with...
Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer
On April 29, 2020, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on...
Expert Point of View: Thomas J. Herzog, MD, and Kathleen N. Moore, MD
Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PAOLA-1 trial findings along with updated results of the PRIMA trial, called the difference in progression-free survival with the addition of olaparib to bevacizumab “remarkable” after ...
Front-Line Maintenance With Olaparib/Bevacizumab Improves Outcomes in Advanced Ovarian Cancer
Proponents of combining bevacizumab with poly (ADP-ribose) polymerase (PARP) inhibition to treat advanced ovarian cancer now have more data to support the maintenance regimen, according to an updated analysis of the phase III PAOLA-1 trial presented during the 2020 Society of Gynecologic Oncology...
KEYNOTE-555 Supports 6-Week Pembrolizumab Dosing Schedule in Melanoma
A less-frequent, more-convenient dosing schedule for pembrolizumab (400 mg every 6 weeks) was deemed safe and effective in patients with unresectable or metastatic melanoma, according to interim data from cohort B enrolled in the KEYNOTE-555 trial. These findings were presented at the 2020 Virtual...
ACS Survey Finds COVID-19 Health Impact Increasing on Patients With Cancer
An American Cancer Society Cancer Action Network (ACS CAN) survey of patients with cancer and survivors, conducted in May 2020, focused on COVID-19 effects. Compared with a survey conducted in April 2020, 87% of respondents said the pandemic had affected their health care, up from 51% in the...
Expert Point of View: Susan Domchek, MD, and Aditya Bardia, MD, MPH
“PARP inhibitors are a major advance in the treatment of BRCA1- and BRCA2-mutated tumors, including prostate, breast, ovarian, and pancreatic cancers,” said discussant Susan Domchek, MD, Director of the Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center in Philadelphia. Nevertheless,...
